The guidance raise and strong beat confirm improving operational momentum and balance sheet deleveraging. However, the Nashik supply disruption creates H2 uncertainty — monitor management's remediation progress and any further guidance revisions. The Gwyn Lo launch and Tyrvaya monetization add pipeline value but are not near-term revenue drivers. The stock may re-rate on the combination of earnings growth and debt reduction, but the $100-150M revenue headwind from Nashik limits upside until resolved.
Price Chart
Executive Summary
Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5% YoY, 2.4% above consensus). The company raised midpoints of all 2026 guidance metrics — revenue to $14.75B, adjusted EBITDA to $4.4B, adjusted EPS to $2.52, and free cash flow to $2.2B — while reducing gross leverage to 2.9x and returning $550M to shareholders. Material headwinds from the Nashik facility disruption ($100-150M H2 revenue impact) are partially offset by FDA approval of Gwyn Lo and the Tyrvaya sale.
Key Financial Metrics
Key Facts
- Q2 adjusted EPS $0.69 vs consensus $0.60 (+15% beat)
- Total revenue $3.76B vs consensus $3.67B (+2.4% beat); reported growth +5%, operational +4%
- Raised 2026 guidance midpoints: revenue $14.75B (from $14.70B), adj. EBITDA $4.40B (from $4.30B), adj. EPS $2.52 (from $2.40), FCF $2.20B (from $2.15B)
- Gross leverage ratio reduced to 2.9x; $900M debt repaid, refinanced with €650M notes
- Returned ~$550M to shareholders YTD including $270M in share repurchases at $16.42 avg
- FDA approved Gwyn Lo contraceptive patch; signed Tyrvaya sale for $30M upfront + $70M milestones
- Nashik facility disruption expected to impact $100-150M of H2 2026 total revenue
- Adjusted EBITDA $1.19B (+10% reported, +8% operational); free cash flow ex-items $449M in Q2
Financial Impact
Guidance midpoint raise of $0.12 on adjusted EPS (+5%) and $100M on EBITDA (+2.3%) vs. prior guidance, partially offset by $100-150M Nashik revenue headwind
Risk Factors
- Nashik facility disruption could be worse than guided $100-150M hit to H2 revenue
- Generics pricing pressure and competition on key brands (EpiPen, Lyrica, Viagra)
- Currency headwinds from strong USD (operational growth 3.5% vs reported 5%)
- Execution risk on new product launches (Gwyn Lo, MR-107A-02) and pipeline milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001792044-26-000037 |
| Document: vtrs-20260806.htm | 0001792044-26-000037 |
| Document: 0001792044-26-000037-index-headers.html | 0001792044-26-000037 |
| Document: 0001792044-26-000037-index.html | 0001792044-26-000037 |
| Document: 0001792044-26-000037.txt | 0001792044-26-000037 |
| 8-K Data (Synthetic) | 0001792044-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.29 $16.94 | ▲ +3.99% | ▲ +3.39% | $17.60 (+8.04%) |
Jun 25, 2026 14w ago | 144 | $16.33 $17.28 | ▲ +5.82% | ▲ +4.56% | $17.60 (+7.78%) |
Jun 18, 2026 15w ago | 8-K | $15.38 $17.29 | ▲ +12.42% | ▲ +12.57% | $17.60 (+14.43%) |
Jun 15, 2026 15w ago | 8-K | $16.04 $16.31 | ▲ +1.68% | ▲ +1.48% | $17.60 (+9.73%) |
May 13, 2026 20w ago | Court Ruling | $17.37 $16.31 | ▼ −6.10% | ▼ −5.49% | $17.60 (+1.32%) |
May 7, 2026 21w ago | 8-K | $17.39 $15.56 | ▼ −10.52% | ▼ −13.66% | $17.60 (+1.21%) |
May 4, 2026 21w ago | 8-K | $15.52 $15.69 | ▲ +1.10% | ▼ −3.86% | $17.60 (+13.40%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
Apr 13, 2026 24w ago | Court Ruling | $13.83 $16.92 | ▲ +22.34% | ▲ +14.59% | $17.60 (+27.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access